Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Prepare for your retirement planning by knowing what to ask a financial planner. These key questions will guide your discussions.
18,106 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
As AI workloads surge, power reliability becomes a strategic bottleneck for data centers. This utility stock could of...
A nationwide lettuce recall disrupts menus and weighs on restaurant margins. Investors watch producers and chains as ...
A single director's sale at MannKind raises questions about the durability of royalty streams. This analysis breaks d...
A year after federal funding ended, South Dakota's public media network stays on air thanks to local support, partner...
A sizable fund disclosed a multi-million Braze stake as the stock faced a steep drop. This article explains what the ...
A week after Walmart’s investor day, the stock surged as analysts highlighted margin discipline and cash returns. Thi...
A Supreme Court ruling nullifies broad tariffs, but a mid-sized U.S. coffee roaster warns refunds are unlikely and co...
Teladoc has faced a challenging stretch after its pandemic boom. This guide examines whether teladoc stock going read...
A high-profile stage moment reshaped Jelly Roll's narrative, but off-camera leaks can quietly alter financial outcome...
A major investment manager recently disclosed a sizable position in Varonis Systems. This article unpacks what the mo...
When a major tariff ruling shifts import costs, retail stocks can respond quickly. This article breaks down why these...